Mankind Pharma Ltd

Securities in F&O Ban: Sammaan Capital shares are banned from F&O trading on 04 February 2026. Result Today: Archean Chemical Industries, Apollo Tyres, Aptus Value Housing Finance India, Aurionpro Solutions, Automotive Axles, Avalon Technologies, Bajaj Finserv, Bajaj Holdings & Investment, Carysil, CCL Products (India), Century Plyboards (India), Cera Sanitaryware, Cummins India, Devyani International, Emami, Emcure Pharmaceuticals, Eureka Forbes, Force Motors, Gallantt Ispat, Greenply Industries, Hexaware Technologies, Inventurus Knowledge Solutions, Jain Irrigation Systems, Jaiprakash Power Ventures, JSW Cement, Jubilant Ingrevia, Kalpataru Projects International, Lloyds Engineering Works, Global Health, Metropolis Healthcare, NHPC, Parag Milk Foods, Apeejay Surrendra Park Hotels, Pokarna, Quality Power Electrical Equipments, Redington, RITES, Rane (Madras), Keystone Realtors, Saatvik Green Energy, Sammaan Capital, Shipping Corporation of India Land and Assets, Tata Power Company, Transport Corporation of India, TeamLease Services, Tube Investments of India, Timken India, Tamilnad Mercantile Bank, Trent, Welspun Enterprises, Westlife Foodworld, Wonderla Holidays and Xpro India will announce their quarterly earnings today. Stocks to Watch: Bajaj Finance reported 6.33% decline in consolidated net profit to Rs 3,977.85 crore in Q3 FY26 compared with Rs 4,246.54 crore in Q3 FY25. Total revenue from operations jumped 17.63% YoY to Rs 21,213.89 crore in Q3 FY26. Mankind Pharma reported a 7.6% year-on-year increase in consolidated net profit to Rs 409 crore, driven by an 11.5% rise in revenue from operations to Rs 3,567 crore in Q3 FY26, compared with Q3 FY25. Godrej Agrovet posted a 3% year-on-year growth in consolidated net profit to Rs 115 crore, while revenue increased 11% to Rs 2,718 crore in Q3 FY26 over Q3 FY25. Rubucon Research reported 91.2% jump in consolidated net profit to Rs 72.8 crore on 51.7% increase in revenue from operations to Rs 475.5 crore in Q3 FY26 over Q3 FY25. Aditya Birla Capital's consolidated net profit jumped 33.48% to Rs 945.02 crore on 27.4% increase in revenue from operations to Rs 11952.09 crore in Q3 FY36 over Q2 FY25.Powered by Capital Market - Live

Mankind Pharma announced that ICRA has assigned the rating ICRA AA+; Stable / ICRA A1+ for debt facilities of the company including non-convertible debentures. The rating on commercial paper of ICRA A1+ has been withdrawn. Powered by Capital Market - Live

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 3 February 2026.Powered by Capital Market - Live

Mankind Pharma Ltd is up for a fifth straight session today. The stock is quoting at Rs 2228.7, up 1.94% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.01% on the day, quoting at 26175.65. The Sensex is at 85535.57, down 0.04%. Mankind Pharma Ltd has gained around 0.27% in last one month. Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has gained around 1.82% in last one month and is currently quoting at 22927.9, down 0.11% on the day. The volume in the stock stood at 3.36 lakh shares today, compared to the daily average of 4.94 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 2231.3, up 2.1% on the day. Mankind Pharma Ltd is down 23.43% in last one year as compared to a 10.32% jump in NIFTY and a 1.52% jump in the Nifty Pharma index.The PE of the stock is 54.2 based on TTM earnings ending September 25.Powered by Capital Market - Live

Mankind Pharma has allotted 46,582 equity shares under ESOP on 26 November 2025. With this allotment, the paid up equity share capital has increased to 41,28,05,072 equity shares having face value of Re 1/- each. Powered by Capital Market - Live

Mankind Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 2222.3, down 0.64% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.14% on the day, quoting at 25609.05. The Sensex is at 83614.62, up 0.09%.Mankind Pharma Ltd has eased around 9.02% in last one month.Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has increased around 0.57% in last one month and is currently quoting at 22379.85, down 0.22% on the day. The volume in the stock stood at 2.28 lakh shares today, compared to the daily average of 3.64 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 2231.5, down 0.72% on the day. Mankind Pharma Ltd tumbled 15.25% in last one year as compared to a 7.23% rally in NIFTY and a 0.81% spurt in the Nifty Pharma index.The PE of the stock is 55.39 based on TTM earnings ending September 25.Powered by Capital Market - Live

Net profit of Mankind Pharma declined 21.72% to Rs 511.51 crore in the quarter ended September 2025 as against Rs 653.47 crore during the previous quarter ended September 2024. Sales rose 20.77% to Rs 3697.16 crore in the quarter ended September 2025 as against Rs 3061.43 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales3697.163061.43 21 OPM %24.9227.67 - PBDT845.84951.72 -11 PBT624.02851.23 -27 NP511.51653.47 -22 Powered by Capital Market - Live

Mankind Pharma has received reaffirmation in credit ratings from CRISIL at CRISIL AA+/ Stable / CRISIL A1+. Powered by Capital Market - Live

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 6 November 2025.Powered by Capital Market - Live

Mankind Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 2496.5, down 1.18% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.54% on the day, quoting at 24755.4. The Sensex is at 80723.46, down 0.54%.Mankind Pharma Ltd has gained around 0.91% in last one month.Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has eased around 1.23% in last one month and is currently quoting at 21977.7, down 1.99% on the day. The volume in the stock stood at 2.14 lakh shares today, compared to the daily average of 3.32 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 2494.1, down 1.24% on the day. Mankind Pharma Ltd tumbled 3.68% in last one year as compared to a 5.44% slide in NIFTY and a 8.41% fall in the Nifty Pharma index.The PE of the stock is 57.48 based on TTM earnings ending June 25.Powered by Capital Market - Live